INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Core Insights - Phio Pharmaceuticals Corp. is presenting data on its proprietary INTASYL® siRNA gene silencing technology at the 20th Annual Oligonucleotide Therapeutics Society Meeting in Montreal from October 6th-9th, 2024 [3][4] - The presentation will highlight how INTASYL enhances the ex vivo expansion process to improve the functionality and outcomes of adoptive cell therapies, including NK, TIL, and CAR-T [4] - INTASYL technology is noted for its simplified chemical composition, which aims to reduce toxicity while improving tolerability and efficacy in therapeutic development [4][5] Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology [5] - INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types, primarily enhancing the ability of immune cells to kill tumor cells [5] - INTASYL is unique as it is the only self-delivering RNAi technology that does not require specialized formulations or drug delivery systems [5]